PVX2 / PapiVax - LARVOL DELTA

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting ➔ Completed

Trial completion • Cervical Cancer • Oncology • Solid Tumor

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Mar 2024 ➔ Dec 2024

Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

PVX-2: Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL (clinicaltrials.gov) - P2 | N=16 | Terminated | Sponsor: PapiVax Biotech, Inc. | N=134 ➔ 16 | Recruiting ➔ Terminated; Slow recruitment/funding

Cytology • Enrollment change • Trial termination

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jan 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor • CD4

SAFETY RUN-IN OF INTRAMUSCULAR PNGVL4A-SIG/E7(DETOX)/HSP70 DNA AND TA-CIN PROTEIN VACCINATION AS TREATMENT FOR HPV16+ ASC-US, ASC-H, OR LSIL/CIN1 (IPVC 2023) - P2 | "At month 6, 45% (5/11) of participants converted to HPV16-negative and 2 others developed CIN2+ and received a LEEP. At month 12, 64% (7/11) were HPV16-negative, including those HPV16-negative at month 6.Conclusions The PVX2 immunotherapy was well tolerated and associated with viral regression, supporting further testing."

Clinical • Gynecology • Infectious Disease